Jonathan Grady, MD
Ophthalmology · Lake Jackson, TXNPI 1386838563
Payments from drug & device makers
Across 553 payments — averaging $392.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$211K
- Beaver-visitec International, Inc.$2K
- Sun Pharmaceutical Industries Inc.$885
- Alcon$587
- Harrow Eye, LLC$383
- Bausch & Lomb Americas Inc.$303
- plus $2K from 23 others
What the payments were for
- Consulting fees$8630%
- Speaking & faculty fees$165,55076%
- Travel & lodging$35,66216%
- Food & beverage$13,5946%
- Education$1,5291%
- Gifts$1080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 389 | $211,138 |
| Beaver-visitec International, Inc. | 4 | $1,698 |
| Sun Pharmaceutical Industries Inc. | 44 | $885 |
| Alcon | 22 | $587 |
| Harrow Eye, LLC | 14 | $383 |
| Bausch & Lomb Americas Inc. | 6 | $303 |
| Tarsus Pharmaceuticals, Inc. | 6 | $296 |
| Novartis | 14 | $285 |
| Carl Zeiss Meditec USA, Inc. | 3 | $213 |
| Sight Sciences, Inc. | 6 | $158 |
| NEW World Medical,inc. | 1 | $143 |
| Oyster Point Pharma, Inc. | 5 | $124 |
| Glaukos Corporation | 5 | $121 |
| Haag-streit USA, Inc. | 2 | $119 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $116 |
| Aerie Pharmaceuticals, Inc. | 5 | $112 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $109 |
| Kala Pharmaceuticals, Inc. | 5 | $95 |
| Dompe US, Inc. | 3 | $72 |
| Carl Zeiss Meditec, Inc. | 1 | $65 |
| Johnson & Johnson Vision Care, Inc. | 2 | $62 |
| Ivantis, Inc | 2 | $47 |
| Rxsight Inc | 3 | $43 |
| Shire North American Group Inc | 1 | $25 |
| Biotissue Holdings Inc. | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Thea Pharma Inc. | 1 | $22 |
| Amgen | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$203,990
- XEN GLAUCOMA TREATMENT SYSTEM$675
- LUMIGAN$639
- VUITY$372
- XEN$267
- XDEMVY$146
- MIEBO$145
- XIIDRA$145
- enVista MX60 IOL$145
- LUMERA 700$139
- Rocklatan$133
- Rhopressa$133
- COMBIGAN$125
- RESTASIS$124
- VEVYE$124
- LOTEMAX SM$116
- PROLENSA$116
- ZYLET$116
- ENVISTA TORIC$116
- STELLARIS$116
How this compares
$217,305 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 511 | $329,887 |
| RestasisCyclosporine | 114 | $131,627 |
| XiidraLifitegrast | 87 | $100,794 |
| CombiganBrimonidine Tartrate/Timolol | 148 | $74,000 |
| CequaCyclosporine | 54 | $50,412 |
| RocklatanNetarsudil Mesylat/Latanoprost | 67 | $35,235 |
| TyrvayaVarenicline Tartrate | 30 | $20,315 |
| VyzultaLatanoprostene Bunod | 40 | $20,299 |
| Travatan ZTravoprost | 34 | $18,930 |
| RhopressaNetarsudil Mesylate | 37 | $17,779 |
| Alphagan PBrimonidine Tartrate | 41 | $15,144 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 57 | $13,086 |
| Cyclosporine | 17 | $12,703 |
| Difluprednate | 65 | $7,521 |
| Bromfenac Sodium | 58 | $6,874 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $211,138 | $550,659814 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $303 | $121,093127 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $112 | $53,014104 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $885 | $50,41254 claims |
| NovartisTravatan Z, Ilevro | $285 | $25,16651 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $124 | $20,31530 claims |
| AlconSimbrinza | $587 | $6,36428 claims |
| Thea Pharma Inc.Iyuzeh | $22 | $5,94312 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $18 | $4,15518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Lake Jackson
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Patrick WilliamsArlington$6.6M
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Michael SingerSan Antonio$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.